A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

1. Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent

2. Must be a candidate for phototherapy or systemic treatment for psoriasis (either newto treatment or having had previous treatment)

Exclusion Criteria:

1. History of or current signs or symptoms of severe, progressive, or uncontrolledrenal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,neurologic, cerebral, or psychiatric disease

2. Participant has history of erythrodermic psoriasis, generalized or localizedpustular psoriasis, medication-induced or medication-exacerbated psoriasis, or newonset guttate psoriasis

3. Has received any therapeutic agent directly targeted to IL-17within 6 months of thefirst administration of study agent

4. Has received any therapeutic agent directly targeted toTNF-a within 3 months of thefirst administration of study agent

5. Has received any conventional therapeutic agent within 1 months of the firstadministration of study agent

6. Has received any topic therapeutic agent within 2 weeks of the first administrationof study agent